Validation of nigrostriatal positron emission tomography measures: Critical limits
| Autor: | Tom O. Videen, Hubert P. Flores, Stephen M. Moerlein, LinLin Tian, Joel S. Perlmutter, Susan K. Loftin, Christopher A. Brown, Morvarid Karimi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Pathology
medicine.medical_specialty medicine.diagnostic_test Tetrabenazine MPTP Magnetic resonance imaging Substantia nigra nervous system diseases Clinical trial chemistry.chemical_compound nervous system Neurology chemistry Positron emission tomography medicine Clinical endpoint MPTP Poisoning Neurology (clinical) Psychology medicine.drug |
| Zdroj: | Annals of Neurology. 73:390-396 |
| ISSN: | 0364-5134 |
| DOI: | 10.1002/ana.23798 |
| Popis: | Objective Molecular imaging and clinical endpoints are frequently discordant in Parkinson disease (PD) clinical trials raising questions about validity of these imaging measures to reflect disease severity. We compared striatal uptake for 3 PET tracers with in vitro measures of nigral cell counts and striatal dopamine in MPTP treated monkeys. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text